Showing results (171-180 of 6,853) with videos related to
Sort By:
Pageof 686
Journal of Medical Economics|March 26, 2010
The economic value of reducing medication dosing frequency with drug delivery technologies: an evidence assessmentMindy M Cheng, Rafael Alfonso, Jennie H Best, et al.Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|August 2, 2008
Economic evaluation of influenza pandemic mitigation strategies in the United States using a stochastic microsimulation transmission modelBeate Sander, Azhar Nizam, Louis P Garrison, et al.Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 21, 2015
The Lifetime Economic Burden of Inaccurate HER2 Testing: Estimating the Costs of False-Positive and False-Negative HER2 Test Results in US Patients with Early-Stage Breast CancerLouis P Garrison, Joseph B Babigumira, Anthony Masaquel, et al.Journal of Medical Economics|May 4, 2019
Tumor treating fields and maintenance temozolomide for newly-diagnosed glioblastoma: a cost-effectiveness studyGregory F Guzauskas, Erqi L Pollom, Volker W Stieber, et al.Genetics in Medicine : Official Journal of the American College of Medical Genetics|July 28, 2012
Stakeholder perspectives on decision-analytic modeling frameworks to assess genetic services policyGregory F Guzauskas, Louis P Garrison, Jacquie Stock, et al.Plos One|January 31, 2025
A prospective model of the potential clinical and economic impact of cervical cancer screening supported by a mobile phone appFredrick Chite Asirwa, Brian W Bresnahan, Faith Yego, et al.Applied Health Economics and Health Policy|June 26, 2021
EQ-5D-5L Health-State Values for the Mexican PopulationCristina Gutierrez-Delgado, Rosa-María Galindo-Suárez, Cesar Cruz-Santiago, et al.Diabetes Care|January 29, 2011
Weight-related quality of life, health utility, psychological well-being, and satisfaction with exenatide once weekly compared with sitagliptin or pioglitazone after 26 weeks of treatmentJennie H Best, Richard R Rubin, Mark Peyrot, et al.BMC Health Services Research|May 4, 2021
Challenges in valuing and paying for combination regimens in oncology: reporting the perspectives of a multi-stakeholder, international workshopNicholas R Latimer, Daniel Pollard, Adrian Towse, et al.International Journal of Technology Assessment in Health Care|February 4, 2016
UNDERSTANDING VARIATIONS IN RELATIVE EFFECTIVENESS: A HEALTH PRODUCTION APPROACHAdrian Towse, Bengt Jonsson, Clare McGrath, et al.Pageof 686